Abstract：Objective To analyze the correlation between the results of galacto-mannan (GM) test in bronchoalveolar fluid (BALF) and the positive results of invasive pulmonary aspergillus. Methods From January 2014 to December 2016, 8086 BALF and 1459 serum from patients with respiratory disease in 650 cooperative medical institutions (including tertiary, secondary and community hospitals) in Zhejiang Province were collected. By using the GM test kits to carry out GM experiments in BALF and serum samples according to the instructions of the kit, the diagnostic value of the invasive pulmonary aspergillosis (IPA) was analyzed by the results of the I value, the IPA diagnosis compliance rate was analyzed with BALF results. Fungal culture was carried out in a conventional manner by using sand-fortified medium. Aspergillus identification: the fungal from the positive samples were cultured, so they could be subjected to 10% KOH based smear before microscopic observation, and then the Aspergillus were differentiated by their morphology and color. Results There were 1193 Aspergillus positive specimens among these 8086 BALF samples. In the Aspergillus positive samples, according to the results of I value of GM test: <0.5 for 61 cases (5.11%), 0.5 to 1 for 98 (8.21%), 1.1-2.0 for 164 (9.56%) and ＞2.1 for 870 (77.12%); and in 5103 cases which had no fungal growth, the results of I value of GM test was: <0.5 for 3623 cases (70.99%), 0.5-1 for 827 cases (16.21%), 1.1-2.0 for 376 cases (7.37%) and >2.1 for 277 cases. There was a significant difference between these two groups (P ＜ 0.01). There also was a significant difference between the Aspergillus positive group and the Candida positive group (P ＜ 0.01). The analysis of I value of GM test in BALF and invasive pulmonary aspergillosis (IPA) diagnostic coincidence rate: When the I value was set to ≥2.1, the sensitivity, specificity, positive predictive value and negative predictive value of IPA diagnosis were as follows: 77.12% 94.57%, 76.86% and 76.85%, the differences were statistically significant (P ＜ 0.01); with the analysis thatwhen I value was set to be≥0.5 for positive results (94.89%, 9.00%, 43.34% and 43.34%, respectively). The results of GM test in serum showed that the I value of the Aspergillus positive group was 0.5.63%, and the growth without fungal was only 6.54%, the differences were statistically significant (P ＜ 0.01). Conclusion When the I value is set to ≥2.1, the result of the GM test in BALF is significantly more valuable. When the I value isset to ≥0.5, the I value of GM test in serumis more appropriate.
[1] Hsu LY，Ng ES，Koh LP. Common and emerging fungal pulmonary in fections [J]. Infect Dis Clin North Am，2010，24（3）：557-577．
[2] Smith JA，Kauffman CA. Pulmonary fungal infections [J]. Respirology，2012，17（6）：913-926．
[3] Pini P，Bettua C，Orsi CF，et al. Evaluation of serum（1-3）-β-d-glucan clinical performance：Kinetic assessment， comparison with galactomannan and evaluation of confounding factors [J]. Infection，2016，44（2）：223-233.
[4] Metan G，Keklik M，Din? G，et al. Performance of Galactomannan Antigen，Beta-d-Glucan，and Aspergillus-Lateral-Flow Device for the Diagnosis of Invasive Aspergillosis [J]. Indian J Hematol Blood Transfus，2017，33（1）：87-92.
[5] De PB，Walsh TJ，Donnelly JP，et al. Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group（EORTC/ MSG）Consensus Group [J]. Clin Infect Dis，2008，46（12）：1813-1821.
[6] 中华医学会呼吸病学分会感染学组.中华结核和呼吸杂志编辑委员会肺真菌病诊断和治疗专家共识[J].中华结核和呼吸杂志，2007，30（11）：821-834.
[7] 中华内科杂志编辑委员会.侵袭性肺部真菌感染的诊断标准与治疗原则（草案）[J].中华内科杂志，2006，45（8）：697-700.
[8] Miceli MH，Maertens J. Role of Non-Culture-Based Tests，with an Emphasis on Galactomannan Testing for the Diagnosis of Invasive Aspergillosis [J]. Semin Respir Crit Care Med，2015，36（5）：650-661.
[9] 朱旭华，王笑云，张华根，等.肺泡灌洗液G试验对侵袭性肺真菌感染的早期诊断价值[J].中国医药导报，2017， 14（10）：75-78.
[10] 汪泽，高艳艳，刘永全，等.表皮生长因子受体信号通路对慢性烟曲霉暴露哮喘大鼠气道重塑的影响[J].中国医药导报，2015，12（12）：4-8.
[11] Ewa SK，Marlena G，KatarzynaP，et al. Aspergillus galactomannan detection in comparison to a real-time PCR assay in serum samples from a high-risk group of patients[J]. Cent Eur J Immunol，2015，40（4）：454-460.
[12] Carmona EM，Limper AH. Diagnosis and Treatment of Fungal Chest Infections [J]. Clin Chest Med，2017，38（3）：xv-xvi.
[13] Quanhathai K，Nagakrishnal N，Luis OZ. Fungal Diagnostics：A Practical Approach[J]. Current Clinical Microbiology Reports，2016，3（2）：103-110.
[14] Khodavaisy S，Hedayati MT，Alialy M，et al. Detection of galactomannan in bronchoalveolar lavage of the intensive care unit patients at risk for invasive aspergillosis [J]. Curr Med Mycol，2015，1（1）：12-17.
[15] Malgorzata M，Elisa F，Claudio V. Non-cultural methods for the diagnosis of invasive fungal disease [J]. Expert Rev Anti Infect Ther，2015，13（1）：103-117.
[16] Savio J，Menon NR，Sudharma AR，et al. Galactomannan Assay and Invasive Pulmonary Aspergillosis-Comparison of the Test Performance at an in-house and the Kit Cut-off [J]. Clin Diagn Res，2016，10（8）：DC1-DC4.
[17] Bellanger AP，Millon L，Berceanu A，et al. Combining Aspergillus mitochondrial and ribosomal QPCR，in addition to galactomannan assay，for early diagnosis of invasive aspergillosis in hematology patients [J]. Med Mycol，2015，53（7）：760-764.
[18] Imbert S，Gauthier L，Joly I，et al. Aspergillus PCR in serum for the diagnosis，follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients [J]. Clin Microbiol Infect，2016，22（6）：562.e1-e8.
[19] Arvanitis M，Anagnostou T，Mylonakis E. Galactomannan and Polymerase Chain Reaction-Based Screening for Invasive Aspergillosis Among High-Risk Hematology Patients：A Diagnostic Meta-analysis [J]. Clinical Infectious Diseases，2015，61（8）：1263-1272.
2018, Vol. 15 
京公网安备 11010502046598号